Full Committee Hearing

COVID-19 and Beyond: Oversight of the FDA’s Foreign Drug Manufacturing Inspection Process

Date: Tuesday, June 2, 2020 Time: 02:30 PM Location: 106 Dirksen Senate Office Building

Open in New Window

Agenda

For this hearing, the Senate Committee on Finance will follow guidelines developed in consultation with the Office of the Attending Physician (OAP), the Senate Sergeant at Arms, and the Senate Rules Committee to protect the health of Members, witnesses, staff and the public. This includes maintaining six-foot social distance spacing in the hearing room.

Pursuant to guidance from the CDC and OAP, Senate office buildings are not open to the public other than official business visitors and credentialed press at this time. Accordingly, in-person visitors cannot be accommodated at this hearing. We encourage the public to utilize the Committee’s livestream of the hearing, available on the website at http://www.finance.senate.gov.   

All hearings are webcast live and will not be available until the hearing starts. Individuals with disabilities who require an auxiliary aid or service, including closed captioning service for webcast hearings, should contact the committee clerk at 202-224-4515 at least three business days in advance of the hearing date.

Questions about the feed or general questions about media attendance can be directed to: Michael_Zona@finance.senate.gov

 

Member Statements

  1.  Chuck Grassley (R - IA)
  2.  Ron Wyden (D - OR)

Witnesses

PANEL ONE

  1. Judith A. McMeekin, Pharm.D.
    Associate Commissioner for Regulatory Affairs, Office of Regulatory Affairs
    Food and Drug Administration
    Silver Spring , MD
  2. Douglas Throckmorton M.D.
    Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research
    Food and Drug Administration
    Silver Spring , MD
  3. Mark Abdoo
    Associate Commissioner for Global Policy and Strategy
    Food and Drug Administration
    Silver Spring , MD
  4. Mary Denigan-Macauley, Ph.D.
    Director, Health Care
    United States Government Accountability Office
    Washington , DC

PANEL TWO

  1. Martin VanTrieste
    President & Chief Executive Officer,
    CivicaRx
    Lehi , UT
  2. David Light
    Founder and CEO
    Valisure
    New Haven , CT

Related Files

Q1a Data for China
Q1b Data for China
Q1a Data for India
Q1b Data for India
Q2 Product List (Part 1)
Q2 Product List (Part 2)
Q2 Product List (Part 3)
Q2 Product List (Part 4)
GFI Production
COVID-19 and Beyond: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process

 How do I submit a statement for the record?

Any individual or organization wanting to present their views for inclusion in the hearing record should submit in a Word document, a single-spaced statement, not exceeding 10 pages in length. No other file type will be accepted for inclusion. Title and date of the hearing, and the full name and address of the individual or organization must appear on the first page of the statement. Statements must be received no later than two weeks following the conclusion of the hearing.

Statements can be emailed to:

Statementsfortherecord@finance.senate.gov

Statements should be mailed (not faxed) to:

Senate Committee on Finance
Attn. Editorial and Document Section
Rm. SD-219
Dirksen Senate Office Bldg.
Washington, DC 20510-6200